Asset profile
Laromestrocel · Lomecel-B
Cell therapy
Evidence outlook · lead readout
NCT05233774 · Mild Alzheimer's Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05233774: The trial used randomized, quadruple-blind, placebo-controlled groups with 50 participants. Its primary endpoints were safety events and MRI findings, but results were not posted, so whether those endpoints were met is unknown; the available design supports moderate rather than strong evidence.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.